₹1,542.95 25.75 (1.70%)
12:37 PM, 16-Dec-2024₹1,541.85 23.70 (1.56%)
12:24 PM, 16-Dec-2024BSE : 532296
NSE : GLENMARK
Sector : Health care
ISIN Code : INE935A01035
Last Updated: 16-Dec-2024 | 12:37 PM IST
Market Cap (₹ Cr) | 43,542 |
Traded Value (₹ Cr) | 1.59 |
Volume (Shares) | 10,335 |
Face Value (₹) | 1 |
52-Week High (₹) | 1,830.05 |
52-Week High Date | 15-Oct-2024 |
52-Week Low (₹) | 766.65 |
52-Week Low Date | 15-Feb-2024 |
All Time High (₹) | 1,830.05 |
All Time High Date | 15-Oct-2024 |
All Time Low (₹) | 1.89 |
All Time Low Date | 10-Feb-2000 |
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 43,511 |
EPS - TTM (₹) [C] | 0.00 |
P/E Ratio (X) [C] | - |
Face Value (₹) | 1 |
Latest Dividend (%) | 250.00 |
Latest Dividend Date | 13-Sep-2024 |
Dividend Yield (%) | 0.16 |
Book Value Share (₹) [C] | 299.29 |
P/B Ratio (₹) [C] | 5.15 |
Scheme Name | Amount Invested (₹ Cr) | No Of Shares | Net Asset (%) |
---|---|---|---|
HDFC Mid-Cap Opportunities Fund (G) | 1182.37 | 77,34,755 | 1.55 |
HDFC Mid-Cap Opportunities Fund (IDCW) | 1182.37 | 77,34,755 | 1.55 |
HDFC Mid-Cap Opportunities Fund - Direct (IDCW) | 1182.37 | 77,34,755 | 1.55 |
HDFC Mid-Cap Opportunities Fund - Direct (G) | 1182.37 | 77,34,755 | 1.55 |
Mirae Asset Large & Midcap Fund - Regular (G) | 463.49 | 30,32,011 | 1.20 |
Mirae Asset Large & Midcap Fund - Regular (IDCW) | 463.49 | 30,32,011 | 1.20 |
Mirae Asset Large & Midcap Fund - Direct (IDCW) | 463.49 | 30,32,011 | 1.20 |
Mirae Asset Large & Midcap Fund - Direct (G) | 463.49 | 30,32,011 | 1.20 |
Mirae Asset ELSS Tax Saver Fund - Regular (G) | 363.09 | 23,75,247 | 1.43 |
Mirae Asset ELSS Tax Saver Fund - Regular (IDCW) | 363.09 | 23,75,247 | 1.43 |
Load more
Today's Low/High (₹) | 1,502.30 1,551.00 |
Week Low/High (₹) | 1,446.50 1,577.00 |
Month Low/High (₹) | 1,446.50 1,597.00 |
Year Low/High (₹) | 771.00 1,831.00 |
All time Low/High (₹) | 1.89 1,831.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 1.86% | 1.83% | 0.24 | 0.00% |
1 Month | 0.66% | 0.53% | 5.31 | 4.62% |
3 Month | -11.48% | -11.46% | -1.55 | -3.01% |
6 Month | 24.73% | 24.63% | 6.12 | 4.92% |
1 Year | 87.02% | 87.12% | 14.29 | 14.74% |
3 Year | 209.58% | 209.58% | 41.11 | 42.73% |
Chairman & Managing Director : Glenn Saldanha
Executive Director (Corporate) : Cheryl Pinto
Executive Director & Group CFO : V S Mani
Non Executive Director : B E Saldanha
Independent Non Exe. Director : Rajesh Desai.
Independent Non Exe. Director : Sona Saira Ramasastry
Independent Non Exe. Director : Dipankar Bhattacharjee
Independent Non Exe. Director : V R Iyer
Registered Office: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road,Mumbai,Maharashtra-400026 Ph: 91-22-40189999
1. What's the Glenmark Pharmaceuticals Ltd share price today?
Glenmark Pharmaceuticals Ltd share price was Rs 1,542.95 at 12:37 PM IST on 16th Dec 2024. Glenmark Pharmaceuticals Ltd share price was up by 1.70% over the previous closing price of Rs 1,517.20. Glenmark Pharmaceuticals Ltd share price trend:
2. How can I quickly analyse the performance of the Glenmark Pharmaceuticals Ltd stock?
The performance of the Glenmark Pharmaceuticals Ltd stock can be quickly analysed on the following metrics:
3. What is the market cap of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd has a market capitalisation of Rs 43,542 crore.
4. What is Glenmark Pharmaceuticals Ltd's 52-week high/low share price?
The Glenmark Pharmaceuticals Ltd’s 52-week high share price is Rs 1,830.05 and 52-week low share price is Rs 766.65.
5. Is the Glenmark Pharmaceuticals Ltd profitable?
On a consolidated basis, Glenmark Pharmaceuticals Ltd reported a profit of Rs 595.06 crore on a total income of Rs 2,719.18 crore for the quarter ended 2024. For the year ended Sep 2024, Glenmark Pharmaceuticals Ltd had posted a profit of Rs 354.49 crore on a total income of Rs 3,473.21 crore.
6. Which are Glenmark Pharmaceuticals Ltd’s peers in the Health care sector?
Glenmark Pharmaceuticals Ltd’s top 5 peers in the Health care sector are Aurobindo Pharma, Alkem Lab, Abbott India, Glenmark Pharma., Biocon, Ipca Labs., Glaxosmi. Pharma.
7. Who owns how much in Glenmark Pharmaceuticals Ltd?
Key changes to the Glenmark Pharmaceuticals Ltd shareholding are as follows: